Glaxosmithkline | GSK - Ebitda

Stock Price
57.45
Daily Change
9.16 18.97%
Monthly
17.94%
Yearly
52.39%
Q1 Forecast
50.58

Glaxosmithkline reported GBP4.75B in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
AbbVie USD 3.52B 828M Sep/2025
Amgen USD 5.91B 2.31B Sep/2025
AstraZeneca USD 4.96B 127M Jun/2025
Aurora Cannabis CAD 15.37M 26.8M Sep/2025
Bausch Health Companies USD 986M 74M Sep/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Canopy Growth CAD 16.62M 38.45M Sep/2025
Corcept Therapeutics USD 27.14M 23.27M Jun/2025
Drreddys Laboratories INR 21.59B 1.49B Dec/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
GlaxoSmithKline GBP 3.36B 179M Sep/2025
Glaxosmithkline GBP 4.75B 1.52B Sep/2025
J&J USD 9.52B 389M Sep/2025
Merck USD 8.39B 1.97B Sep/2025
Novartis USD 5.88B 290M Sep/2025
Pacira USD 49.36M 4.96M Sep/2025
Perrigo USD 258.8M 37.3M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
Prestige Brands USD 86.83M 7.19M Sep/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sanofi EUR 4.84B 2.95B Sep/2025
Supernus Pharmaceuticals USD 41.9M 432K Sep/2025
Takeda JPY 448.13B 173.98B Dec/2025
Teva Pharmaceutical Industries USD 1.64B 243M Dec/2025
Zoetis USD 1.04B 87M Sep/2025